Vera Therapeutics (NASDAQ:VERA) CEO Marshall Fordyce Sells 18,500 Shares of Stock

Posted by Francis Steltz on Jun 24th, 2026

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report) CEO Marshall Fordyce sold 18,500 shares of the business’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $37.93, for a total transaction of $701,705.00. Following the completion of the sale, the chief executive officer directly owned 198,244 shares of the company’s stock, valued at approximately $7,519,394.92. This trade represents a 8.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marshall Fordyce also recently made the following trade(s):

On Tuesday, May 12th, Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock. The shares were sold at an average price of $36.74, for a total transaction of $679,690.00.
On Tuesday, April 14th, Marshall Fordyce sold 22,951 shares of Vera Therapeutics stock. The stock was sold at an average price of $44.05, for a total value of $1,010,991.55.

Vera Therapeutics Stock Performance

Shares of VERA traded up $1.31 during midday trading on Wednesday, reaching $39.51. 2,473,781 shares of the stock were exchanged, compared to its average volume of 1,164,046. The business’s 50-day moving average price is $36.24 and its 200 day moving average price is $41.53. The company has a debt-to-equity ratio of 0.15, a current ratio of 13.64 and a quick ratio of 13.64. Vera Therapeutics, Inc. has a twelve month low of $19.07 and a twelve month high of $56.05. The company has a market capitalization of $2.84 billion, a price-to-earnings ratio of -7.13 and a beta of 0.93.

Vera Therapeutics (NASDAQ:VERA – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same quarter in the previous year, the business earned ($0.81) earnings per share. On average, sell-side analysts expect that Vera Therapeutics, Inc. will post -6.23 EPS for the current fiscal year.

Institutional Trading of Vera Therapeutics

Several hedge funds have recently made changes to their positions in VERA. Price T Rowe Associates Inc. MD increased its stake in shares of Vera Therapeutics by 49.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,461,976 shares of the company’s stock worth $276,595,000 after acquiring an additional 1,795,537 shares during the period. Deerfield Management Company L.P. lifted its position in Vera Therapeutics by 8.8% in the third quarter. Deerfield Management Company L.P. now owns 3,641,157 shares of the company’s stock valued at $105,812,000 after purchasing an additional 293,040 shares during the period. Vanguard Group Inc. boosted its holdings in Vera Therapeutics by 11.9% in the 4th quarter. Vanguard Group Inc. now owns 3,570,401 shares of the company’s stock valued at $180,805,000 after purchasing an additional 379,748 shares in the last quarter. Vestal Point Capital LP boosted its holdings in Vera Therapeutics by 24.0% in the 2nd quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock valued at $73,036,000 after purchasing an additional 600,000 shares in the last quarter. Finally, Eversept Partners LP increased its position in Vera Therapeutics by 9.4% during the 4th quarter. Eversept Partners LP now owns 3,072,304 shares of the company’s stock worth $155,581,000 after purchasing an additional 264,468 shares during the period. Institutional investors and hedge funds own 99.21% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on VERA. TD Cowen reissued a “buy” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Evercore set a $91.00 price target on shares of Vera Therapeutics in a research report on Friday, May 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Monday, April 20th. William Blair reissued an “outperform” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $90.00 price objective on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $78.00.

Read Our Latest Stock Analysis on VERA

About Vera Therapeutics

(Get Free Report)

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.